14CONFAP Application of quantitative proteomics to accelerate vaccine development against Schistosomiasis, a neglected tropical disease.

14CONFAP 应用定量蛋白质组学加速针对血吸虫病（一种被忽视的热带疾病）的疫苗开发。

• 批准号: BB/M028801/1
• 负责人: Robert Beynon
• 金额: $ 5.31万
• 依托单位: University of Liverpool
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FM028801%2F1
• 关键词: 14CONFAP; Application; quantitative; proteomics; accelerate

Schistosomiasis a neglected tropical disease caused by persistent blood-dwelling parasitic worms, is the focus of this application and remains an important public health problem in Brazil. Treatment with the one available drug does not prevent reinfection so an effective vaccine would enhance control. Sequencing of the worm's transcriptome (2003) and genome (2009) has facilitated post-genomic initiatives. Brazilian science would greatly benefit from an injection of cutting-edge proteomic technologies from UK experts to better orientate the search for novel vaccine candidates. As stated above previous collaborations between the proposed partners have led to publications in high impact journals, which in turn have informed the research of vaccinologists in Brazil and worldwide.Proteomics is a young subject, expanding into a very sophisticated technology with enormous potential to illuminate many of the disease problems we face in the developed and developing world alike. The group in Ouro Preto is also in the growth phase. The proposed project could serve as the springboard to establish a longer-lasting collaboration with a leading group of UK researchers at the cutting edge of Proteomics. The impact that this would have on infectious tropical disease research in Brazil cannot be underestimated. The new collaboration will inject advanced proteomic techniques to underpin and consolidate the inventory of novel proteins we expect to identify and quantitate. We anticipate that the collaboration will kick-start a new round of vaccine testing.In this programme, we will apply technologies developed at Liverpool to the analysis of potential vaccine candidates. In particular, Liverpool will host scientists and trainees from Ouro Preto, giving them access the super facilities that are located there. In addition, scientists from Liverpool will visit Ouro Preto to provide advanced training and to deliver a formal training course that will be open to other Brazilian scientists.

血吸虫病是一种被忽视的热带疾病，由持续的血液寄生蠕虫引起，是这种应用的重点，仍然是巴西的一个重要公共卫生问题。用一种可用的药物治疗并不能防止再感染，因此有效的疫苗将加强控制。蠕虫转录组（2003年）和基因组（2009年）的测序促进了后基因组计划。巴西科学将大大受益于英国专家注入的尖端蛋白质组学技术，以更好地定位寻找新的候选疫苗。如前所述，合作伙伴之间的合作已经在高影响力的期刊上发表，这反过来又为巴西和世界各地的疫苗学家提供了信息。蛋白质组学是一门年轻的学科，正在发展成为一门非常复杂的技术，具有巨大的潜力来阐明我们在发达国家和发展中国家面临的许多疾病问题。欧罗普雷托的集团也处于增长阶段。拟议的项目可以作为跳板，与蛋白质组学前沿的英国研究人员建立长期合作。这对巴西热带传染病研究的影响不可低估。新的合作将注入先进的蛋白质组学技术，以支持和巩固我们期望识别和定量的新型蛋白质的库存。我们预计，此次合作将启动新一轮的疫苗测试。在该项目中，我们将应用在利物浦开发的技术来分析潜在的候选疫苗。特别是，利物浦将接待来自欧罗普雷托的科学家和实习生，让他们使用位于那里的超级设施。此外，来自利物浦的科学家将访问欧罗普雷托，提供高级培训，并提供一个正式的培训课程，该课程将向其他巴西科学家开放。